Is AT673 legal in the United Kingdom?

A GIP receptor antagonist being added to semaglutide in a phase 2 trial of 150 people. It is the exact mirror of NNC0480-0389, which adds a GIP agonist to the same drug.

If you want one fact that captures how unsettled incretin pharmacology is, it is this pair. Two companies are in phase 2 adding opposite interventions at the same receptor to the same background drug, for the same indication, at the same time.

Mechanism: An antagonist at the GIP receptor, intended to block rather than activate the receptor tirzepatide agonises, given alongside a GLP-1 receptor agonist. The mechanistic case comes from GIP receptor knockout mice being protected against diet-induced obesity, and from the observation that a naturally occurring truncated GIP fragment blocks its own receptor in humans.

Regulatory history: Investigational. Not approved anywhere. Phase 2 recruiting.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for AT673 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.